Introduction
Dramatic clinical responses have been reported recently using Chimeric antigen receptor (CAR) T cells specific for the B-cell antigen CD19, in patients with chronic and acute lymphocytic leukemia (1, 2) . Similar strategies have been explored in multiple myeloma using CD19 as well as other targets such as BCMA (3, 4) . In our study, we examine the target CS1 and demonstrate that combining immunomodulatory drugs (IMiD) with adoptive cellular therapy (ACT) has the potential for synergistic effects via direct actions on the tumor cells together with IMiD stimulation of CAR T cells.
CS1 is a cell surface glycoprotein of the signaling lymphocyte activation molecule (SLAM) receptor family that is highly and selectively expressed on normal plasma cells and multiple myeloma cells, with lower expression on natural killer (NK) cells and no expression on other normal tissue (5) . CS1 is highly expressed in over 95% of cases of multiple myeloma irrespective of cytogenetic abnormalities and throughout the disease process (5) . The high expression of CS1 on multiple myeloma cells coupled with the lack of or low expression in normal and essential tissues makes CS1 a reasonable target for CAR T-cell therapy against multiple myeloma.
IMiDs, for example, lenalidomide, as a primary treatment modality for multiple myeloma not only yields direct anti-multiple myeloma effects but also costimulates T cells. Both in vitro and in vivo studies demonstrated that lenalidomide enhances tumor-specific Th1 cytokines such as IL2 and IFNg (6, 7), preferentially stimulates CD8 þ T cells (8) , and inhibits IL2-mediated generation of Tregs (9) . In the studies reported here, we investigated the effects of lenalidomide on CS1 CAR T cells in vitro and the anti-multiple myeloma activity in a xenograft mouse model. TNFa, and IL2 and streptavidin-PE (SA-PE) were obtained from BD Biosciences. The antibody against CS1 was purchased from R&D Systems. Biotinylated erbitux was generated from cetuximab purchased from the City of Hope pharmacy. The antibody against EGFR was obtained from eBioscience. All mAbs were used according to the manufacturer's instructions. The percentage of cells in a region of flow cytometric analysis was calculated using FCS Express V4 (De Novo Software).
Lentivirus vector construction
The lentivirus CAR construct was modified from the previously described CD19-specific scFvFc:z chimeric immunoreceptor (10) . The CS1 CAR contained a CS1-specific scFv (CS1R), a CD28z costimulatory domain, an IgG4-Fc spacer with a CH2 deletion to ensure enhanced potency and persistence (11) , and a truncated human EGFR (huEGFRt), which includes a cetuximab (erbitux) binding domain. A T2A ribosome skip sequence links the codonoptimized CS1R:CD28:z sequence to the huEGFRt sequence, resulting in coordinate expression of both CS1R:CD28:z and EGFRt from a single transcript (CS1RCD28EGFRt; ref. 12) . The CS1RCD28EGFRt DNA sequence (optimized by GeneArt) was then cloned into a self-inactivating (SIN) lentiviral vector, pHIV7 (gift from Jiing-Kuan Yee, City of Hope, Duarte, CA).
Cell lines
To generate LCL OKT3, allogeneic LCLs (EBV-transformed lymphoblastoid cell lines) were resuspended in nucleofection solution using the Amaxa Nucleofector kit T. OKT3-2A-Hygromycin_pEK plasmid was added to 5 mg/10 7 cells, the cells were electroporated using the Amaxa Nucleofector I, and the resultant cells were grown in RPMI1640 with 10% FCS containing 0.4 mg/mL hygromycin. MM.1s was cultured in RPMI1640 with 10% FCS, and KG1a was cultured in IMDM with 10% FCS. To generate firefly luciferaseþGFPþMM.1S (fflucGFPMM.1S), MM.1S cells purchased from ATCC were transduced with lentiviral vector encoding eGFP-ffluc. Initial transduction efficiency was 50%, so the GFP cells were sorted by FACS for >98% purity. U266B and MM.1R cells were purchased from ATCC. Banks of all cell lines were authenticated for the desired antigen/marker expression by flow cytometry prior to cryopreservation, and thawed cells were cultured for less than 6 months prior to use in assays. Bone marrow cells were obtained from patients with multiple myeloma under protocols approved by the City of Hope Institutional Review Board.
Generation of multiple myeloma-specific T cells
Leukapheresis products were obtained from healthy donors under protocols approved by the City of Hope Institutional Review Board. Central memory T cells (T CM ) defined as CD45RO þ
CD62L
þ were isolated on Miltenyi autoMACS (Miltenyi Biotec Inc). Briefly, PBMCs were isolated by density gradient centrifugation over Ficoll-Paque (GE Healthcare) and incubated with anti-CD14 and anti-CD45RA microbeads (Miltenyi Biotec Inc) for 30 minutes at room temperature. CD14 þ and CD45RA þ cells were then immediately depleted using the autoMACS. The unlabeled negative fraction of cells was labeled with biotinylated-DREG56 mAb (COHNMC CBG) followed by incubation with anti-biotin microbeads (Miltenyi Biotec Inc). The CD62L þ T CM cells were purified with positive selection on auotMACS. Immediately after selection, the T CM cells were activated, transduced, and maintained as described previously (13) . Cultures were supplemented with lenalidomide every 48 hours for 21 days before in vitro analysis.
Cytokine production A total of 5 Â 10 5 CS1 CAR T cells were cocultured overnight with 5 Â 10 5 LCL OKT3, MM.1S, or KG1a cells in 96-well tissue culture plates. The supernatant was collected, and cytokines were measured with Bioplex cytokine analysis (10-plex kit; in triplicates) according to the manufacturer's instructions.
Intracellular cytokine staining
A total of 5 Â 10 5 CS1 CAR T cells were activated overnight with 5 Â 10 5 LCL OKT3, MM.1S, MM.1R, U266B or KG1a cells in 96-well tissue culture plates in the presence of Brefeldin A (BD Biosciences). The cell mixture was then stained using anti-CD8, anti-CD4, and biotinylated erbitux/streptavidin to analyze surface coexpression of CD8, CD4 and CAR, respectively. Cells were then fixed and permeabilized using the BD Cytofix/Cytoperm kit (BD Biosciences). After fixation, the T cells were stained with antibodies against IFNg, TNFa and IL2. Cells were then analyzed using multicolor flow cytometry on MACSQuant (Miltenyi Biotec Inc.). In some experiments, cocultures were set up in the presence of CS1 protein (BioVision).
Degranulation
A total of 5 Â 10 5 CS1 CAR T cells were cocultured with 2.5 Â 10 5 LCL OKT3, MM.1S, MM.1R, U266B or KG1a cells in RPMI T-cell medium containing Golgi stop (BD Biosciences) and CD107a for 6 hours at 37 C. Degranulation was assessed using multicolor flow cytometry on MACSQuant. In some experiments, cocultures were set up in the presence of CS1 protein (BioVision).
Cytotoxicity assay
Four-hour luciferase-based cytotoxicity assays (LCA) were performed as described previously (14) using CS1 CAR T cells as effector cells and CS1-expressing MM.1S cells as targets.
Translational Relevance
Chimeric antigen receptor (CAR)-directed T-cell therapy is a promising approach for hematologic malignancies, including multiple myeloma; however, uncertainties surround the optimal target as well as enhancing the persistence and expansion of engineered cells in vivo. This study demonstrated that CS1-specific CAR T cells mediated efficient effector function in vitro and anti-multiple myeloma activity in vivo. Furthermore, we explored further improving the function and persistence of these engineered CS1-specific T cells using a combinatorial therapy of CAR T cells with immunomodulatory drugs such as lenalidomide. We found that lenalidomide plays a costimulatory role in modulating CAR T cells and strengthens the antitumor activity and persistence of adoptively transferred CS1 CAR T cells against multiple myeloma in vivo. The rational combination of these immunotherapeutic regimens is an effective strategy for increasing efficacy against multiple myeloma and provides a generalizable approach for combining lenalidomide and CAR T cells.
Side population assay (Hoechst stain)
MM.1S cells were treated with different concentrations of lenalidomide (0, 1, and 10 mmol/L) for 48 hours. Following treatment, cells were washed and resuspended in RPMI at a concentration of 1 Â 10 7 cells/mL. Hoechst dye (Sigma) was added to suspension to achieve a final concentration of 5 mg/mL. Cells were incubated 2 hours with gentle vortexing every 30 minutes. Cells were then spun down at 2,000 rpm for 2 minutes, and media were replaced with Hank balanced salt solution. Propidium iodide (5 mg/mL) was added, and cells were incubated for 5 minutes at 4 C (15, 16). Analysis was conducted on MACSQuant.
Immune synapse staining
In an 8-well chamber, 6 Â 10 4 MM.1S tumor cells were labeled with CellTracker Blue (Life Technologies) to visually distinguish from T cells and seeded in each well. They were cocultured with the same amount of CS1 CAR T cells, which had been treated with different concentrations of lenalidomide. After 2-hour culture at 37 C and 10% CO 2 , the coculture was washed with PBS three times and cells were fixed for 10 minutes with 4% paraformaldehyde (PFA) at 4 C, followed by air dry for 10 minutes, and another wash with PBS.
To detect CAR, the cells were blocked by 0.5% FCS PBS for 1 hour, then 1:150 diluted Fab antibody (goat anti mouse, Sigma, F4018) was added and incubated overnight at 4 C. After washing with 0.5% FCS PBS three times, the cells were stained with secondary antibody against goat (LþH) conjugated with Alexa488 for 1 hour at room temperature. The F-Actin Visualization Kit (Biochem Kit) was used according to the manufacturer's instructions. Briefly, the cells were washed and permeabilized for 5 minutes at room temperature. After one wash with washing buffer, cells were stained with 200 mL working stock Rhodamine Phalloidin and incubated for 30 minutes at room temperature in the dark. After 3 washes, slides were covered by mounting medium. Each sample was duplicated and stained. For FACS-based immune synapse formation analysis (17, 18) Quantitative image analysis of immune synapse Images were taken under microscope (Zeiss observe II, Â40 oil). To quantify immune synapses, entire slides were scanned, and the area of F-actin and Fab conjugation was measured using software (Image propremier 9.2) by setting up the single staining F-actin, Fab, and CellTracker as background. The areas of cell conjugation (yellow-golden brown) were selected for the measurement as polarization of synapse. The exported areas (pixel 2 ) were further analyzed and converted to average pixel 2 for entire slides.
Sequencing library preparation, deep sequencing using Illumina HiSeq2500, and RNA-Seq data analysis
The CD8 þ CAR þ T cells treated with 0, 1, and 10 mmol/L of lenalidomide were purified by FACS after costaining with antibodies against EGFR and CD8. The total RNA was isolated using RNeasy Plus Micro and Mini Kits according to protocol. RNA integrity was verified with the Agilent 2100 Bioanalyzer. The RNA sequencing libraries were prepared using SMARTer Stranded Total RNA-Seq Pico input Kit (Clontech). Briefly, 10 ng of DNA-free total RNA was reverse transcribed by SMARTScribe Reverse Transcriptase with random priming. The enzyme's terminal transferase activity results in addition of a few nontemplated nucleotides to the 3 0 end of the cDNA, creating an extended template to enable the reverse transcriptase to continue replicating to the end of the oligonucleotide. The first round of PCR amplification added full-length Illumina adapters, including barcodes. The ribosomal cDNA (originating from rRNA) was then cleaved by ZapR in the presence of the mammalian-specific R-Probes. The rRNA-depleted cDNA were enriched via a second round of PCR amplification using primers universal to all libraries. The sequencing libraries were validated with running Agilent bioanalyzer DNA high sensitivity Chip, and quantified using Qubit and qPCR. The library templates were prepared for sequencing using cBot cluster generation system with HiSeq PE Cluster Kit V4 (Illumina). Sequencing runs were performed in the paired end mode of 101 cycles of read1, 7 cycles of index read, and 101 cycles of read2 using HiSeq2500 platform with HiSeq SBS Kit V4 (Illumina). Real-time analysis (RTA) 2.2.38 software was used to process the image analysis and base calling.
qPCR analysis
The CD8 þ CAR þ T cells treated with 0, 1, or 10 mmol/L of lenalidomide were purified by FACS after costaining with antibodies against EGFR and CD8. The cells from three different donors were purified and analyzed. The cDNA was used for TaqMan qPCR (7500 FAST, Life Technology). The TaqMan probes used in this study are listed in Supplementary Table S1 . The gene expression levels are presented as 2
DCt
.
Xenograft models
All mouse experiments were approved by the City of Hope Institutional Animal Care and Use Committee. Six-to 10-weekold NOD/Scid IL2RgC null mice were injected intratibially on day 0 with 2 Â 10 6 fflucGFP MM.1S cells. Five days later, mice were injected intravenously with dosed 1 Â 10 6 CAR T cells or nontransduced mock cells. For experiments using lenalidomide, mice were administered 5-7.5 mg/kg of lenalidomide intraperitoneally daily for 30 days. Anesthetized mice were imaged using a Xenogen IVIS 100 series system (Xenogen). Photons from ffLuc þ tumor xenografts were quantified using the software program Living Image (Xenogen), and the bioluminescence signal was measured as total photon flux normalized for exposure time and surface area and expressed in units of photons per second per cm 2 per steradian. Human T-cell engraftment in peripheral blood, bone marrow, and spleen was determined by flow cytometry after staining with antibody against human CD45, CD8, and erbitux for CAR detection.
Statistical analysis
Analyses were performed using Prism (GraphPad Software Inc.). Log-rank (Mantel-Cox) test and Mann-Whitney test were used to ascertain the statistical significance of the in vivo data. The paired t test (two-tailed) and two-way ANOVA were used for the analysis of in vitro data.
Results

CS1 is highly expressed on multiple myeloma cells and primary multiple myeloma bone marrow cells
We conducted flow cytometry to characterize surface CS1 expression on multiple myeloma cells. Multiple myeloma cell line MM.1S cells are highly (70%-80%) CS1-positive. We also assessed antigen expression on bone marrow mononuclear cells from patients with newly diagnosed or relapsed multiple myeloma. Consistently, primary multiple myeloma cells across patients express high levels of CS1 (Fig. 1A) .
Generation of T CM -derived CS1 CAR T cells against multiple myeloma
We isolated T CM cells from healthy donors, followed by activation and transduction with a lentivirus (13) 
CS1 CAR T cells mediate efficient effector function and cytolytic activity
To test the effector function of CS1 CAR T cells, we cocultured expanded CAR T cells with MM.1S cells for 6 hours for degranulation assay and cytokine secretion determination. Gated CS1 CAR T cells express CD107a as an indicator of degranulation and IFNg upon antigen stimulation (Fig. 1D) . We then cocultured CAR T cells with luciferase-expressing MM.1S target cells for 4 hours; specific lysis was analyzed after adding the substrate luciferin (Fig. 1E ). CS1 CAR T cells exhibited specific and efficient killing of multiple myeloma cells.
CS1 CAR T cells exhibit efficient antitumor activity in vivo
A total dose of 1 Â 10 6 CAR T cells specific for CS1 derived from T CM cells were intravenously transferred into MM.1S tumor-bearing mice. CS1 CAR T cells exhibited significantly higher antitumor activity as compared with mock T cells (P ¼ 0.03; Fig. 1F and G).
To further study whether tumor relapse is due to the low dose of CAR T cells, we increased the CS1 CAR T-cell dose 3-fold (3 Â 10 6 ) with the same tumor burden. Tumor recurrence was not delayed (Supplementary Fig. S1 ), which suggested that other mechanisms were at play in regards to disease relapse.
Soluble CS1 does not interfere with CS1 CAR function
Multiple myeloma cells also secrete soluble forms of CS1 and BCMA (19, 20) . Other investigators have previously shown that CAR-expressing T cells were not blocked from recognizing target cells by soluble proteins, including BCMA (21) . CS1 concentrations of >10 times the median CS1 levels found in the serum of patients with multiple myeloma did not block recognition of multiple myeloma cells by CS1 CAR T cells, as indicated by equivalent CD107a degranulation and IFNg production (Supplementary Fig. S2A and S2B ). Furthermore, we analyzed cytolytic activity by adding graded concentrations of CS1 protein during the 4-hour luciferase-based cytolytic assay (LCA). Again, soluble CS1 protein did not interfere with CS1 CAR-specific lysis (Supplementary Fig. S2C ).
Lenalidomide exerts a costimulatory effect on CS1 CAR T cells in a dose-dependent fashion
Lenalidomide has known activity in the activation and expansion of normal T cells (22) . We engineered and expanded CS1 CAR T cells in the presence of 0, 1, and 10 mmol/L lenalidomide. We found that lenalidomide preferentially expanded the CD8 þ CAR T-cell subset in a dose-dependent manner ( Fig. 2A) (24) . We also demonstrated that lenalidomidetreated CS1 CAR T cells exhibited higher Th1 cytokine production, including IFNg and TNFa, as measured in both the supernatant of cocultures and cell-based intracellular cytokine analysis ( Fig. 2C and D) in a dose-dependent manner. Interestingly, autocrine IL2, the major determinant of CAR T-cell potency and persistence, was greatly elevated in the CS1 CAR T cells treated with lenalidomide. However, the production of Tcell immunosuppressive Th2 cytokines (e.g., IL5, IL10, and IL4) was greatly reduced (Fig. 2C ). Lenalidomide exhibited a costimulatory function similarly on CD8
To prove these results are independent of multiple myeloma cell lines, we tested two other multiple myeloma cells, MM.1R and U266B, representing CS1 high and low expressers (Fig. 3A) . Upon stimulation with targets, CS1 CAR T cells express CD107a and secrete IFNg and TNFa against all the multiple myeloma cells tested. The effector functions are correlated with the CS1 expression levels on the targets (Fig.  3B) . Consistently, lenalidomide-treated CS1 CAR T cells exhibited better effector function against different multiple myeloma targets in a dose-dependent manner (Fig. 3C ).
Lenalidomide eradicates multiple myeloma-initiating cells without downregulating CS1 expression on multiple myeloma cells
We assayed the sensitivity of MM.1S cells to lenalidomide as well as the maintenance of surface CS1 during lenalidomide treatment. The overall growth of MM.1S cells was greatly inhibited by the addition of lenalidomide every other day in the culture, indicating that MM.1S cells are sensitive to lenalidomide in vitro ( Supplementary Fig. S5A ). We performed flow cytometry-based Hoechst staining to evaluate the existence of a multiple myeloma tumor-initiating population with stem-like features known as side population cells (SP). Forty-eight hours after treatment of CS1 CAR T cells, a dramatic decrease of SP was observed in the treated MM.1 S cells (Supplementary Fig. S5B ). Meanwhile, lenalidomide did not downregulate CS1 expression on the MM.1S cells, assuring intact antigen for CAR T-cell targeting ( Supplementary  Fig. S5C ). 
Lenalidomide improves immune synapse formation between CAR T cells and tumor cells
The term immunologic synapse (IS) refers to the organization of membrane proteins that occurs at the interface between the T cell and the target cells when contact is made during the effector phase (25) . The enhancement of immune function by lenalidomide on CAR T cells may be related to increased immune synapse formation. We cocultured CAR T cells that had been treated with lenalidomide with target cells for 2 hours. The areas of cell conjugation and polarization between Fabpositive CAR T cells and CellTracker-labeled tumor cells were defined as immune synapses and were quantified using average pixel 2 . We also directly measured the numbers of conjugates as a result of immunologic synapse formation between CS1 CAR T cells and MM.1S target cells using flow cytometry (18) . Consistently, immune synapse formation was found to be significantly increased with the lenalidomide-treated CS1 CAR T cells as compared with untreated CS1 CAR T cells ( Fig. 4A-C ; Supplementary Fig. S6A ). No immune synapse formation was observed when CS1 CAR T cells were cocultured with KG1a or mock T cells were cocultured with MM.1S cells ( Fig. 4D ; Supplementary Fig. S6B and S6C ). In concert with these findings, cytolytic activity was increased with lenalidomide-treated CAR T cells in a dose-dependent fashion, which became especially apparent when a low effector:target (E:T) ratio was used ( Fig. 4E and F) . These data support that enhanced immune synapse formation is associated with the improved cytolytic activity of CAR T cells.
Lenalidomide enhances transcriptional signatures of immune synapse and T-cell function
We sought to compare the transcriptome of the CAR T cells treated with and without lenalidomide. RNA-seq gene expression analysis was conducted with purified CD8 (30) , which all responded in a dose-dependent manner (Fig. 5D ). In contrast, exposure to lenalidomide suppresses genes in CAR T cells that are associated with exhaustion such as PDCD1, CD160 (31, 32), terminal differentiation genes such as GZMK and GZMH, EOMES (33, 34) and immune suppression signals such as TGFBR3 and IL10 (35; Fig. 5E ). Collectively, these findings align with the changes noted above supporting that lenalidomide exerts a costimulatory effect on CS1 CAR T cells. To rule out donor-dependent factors, we purified CD8 þ CAR þ cells from three different donors and analyzed the expression of representative genes. Consistently, dose-dependent effects of lenalidomide on CAR T cells were observed ( Fig. 5F-H) .
Lenalidomide improves CS1-targeted anti-multiple myeloma activity and prolongs functional CAR T-cell persistence in vivo
We investigated the synergistic effects of CS1 CAR T cells and lenalidomide against multiple myeloma in our established xenograft mouse model (Fig. 6A) . Although 5-7.5 mg/kg lenalidomide daily injection alone and mock T cells plus daily injection of lenalidomide did not induce tumor regression, a single CS1 CAR T-cell infusion in conjunction with lenalidomide induced complete tumor remission during lenalidomide treatment (30 days; Supplementary Fig. S7 ) and significantly prolonged survival (P ¼ 0.008 and P ¼ 0.001; Fig. 6B ) as compared with the group treated with CS1 CAR T cells alone. Fifty days after CAR T-cell infusion, CAR T cells were detected only in the group of mice administered both CS1 and lenalidomide, but not in mice given CS1 CAR T cells alone, suggesting improved CAR T-cell persistence with lenalidomide (Fig. 6C) . Upon further evaluation, we found that persisting CAR T cells in the group receiving lenalidomide and CS1 CAR combinatorial treatment were predominantly CD8 þ , in contrast to the input CAR T cells that were CD4
þ dominant, which is consistent with the in vitro data showing enhanced CD8 þ CAR T-cell expansion (Fig. 6D) .
We observed that mice treated with combining CAR T cells and daily injection of lenalidomide remain tumor free. However, relapse occurs once ceasing lenalidomide treatment for two weeks ( Supplementary Fig. S7 ), suggesting that lenalidomide is required for durable tumor regression as it is used in the clinic as a longterm maintenance therapy. We further investigated whether the presence of lenalidomide is needed for sustained and enhanced CAR T-cell function in vivo. CS1 CAR T cells treated ex vivo with and without lenalidomide were injected into multiple myelomabearing mice without giving exogenous lenalidomide administration. Consistently, no improved antitumor activity was observed when mice were treated with the lenalidomide pretreated CAR T-cell products as compared with untreated CS1 CAR T cells (Supplementary Fig. S8 ). To further support this scenario, we performed an experiment where we treated the CS1 CAR T cells with lenalidomide for two weeks. We then split the culture into IFNγ (pg/mL) two, one culture underwent continued lenalidomide treatment every other day for an additional two weeks and the other culture was no longer treated with lenalidomide. Consistently, in the culture with continued lenalidomide, we observed increased levels of CD107a and percentages of CD8 þ T cells at the end of the experiment, compared with values of untreated cultures. We also noted increased intracellular IL2, which is a hallmark of T-cell persistence and function. However, discontinuation of lenalidomide resulted in decreased IL2 production and a lower percentage of CD8 þ T cells, while CD107a levels remained the same. In addition, CAR T cells expressed higher levels of PD1 upon discontinuation of lenalidomide ( Supplementary Fig. S9 ). Overall, our data indicated that the costimulatory effects of CAR T cells mediated by lenalidomide rely on the continuing activation of the T-cell signaling pathway. The role of lenalidomide in this context is therefore not an enhancement during manufacturing but rather a combinatorial agent that improves the function of these CAR T cells.
Discussion
In this study, we demonstrate that CS1 CAR T cells exhibit efficient anti-multiple myeloma activity in vivo. Second, we show that lenalidomide, in addition to its known antimyeloma effects, can also augment T-cell function and number. This in turns leads to a synergistic increase in the antimyeloma activity of CAR T cells through increased cytotoxicity and improved persistence of the engineered cells.
To antigen-dependent effector function as indicated by degranulation and cytokine production, supporting a selective targeting for multiple myeloma cells which express high CS1 on the surface. More interestingly, CS1 CAR T cells exhibited efficient effector function against MM.1R, which are resistant to dexamethasone because of mutant glucocorticoid receptor (36, 37) . These data may indicate the effectiveness of CS1 CAR T cells on dexamethasone-resistant patients with multiple myeloma. Although significant tumor remission was observed in the CS1 CAR T-cell-treated mice, tumor relapse eventually occurred. We first speculated that tumor antigen escape was the cause. Unexpectedly, recurrent tumors remained CS1-positive regardless of CS1 CAR T-cell treatment. We further evaluated CAR T-cell persistence in the tumor-bearing mice, as lack of CAR T-cell persistence is another contributor to failure of T-cell therapy, and greater T-cell persistence and survival are associated with high rates of complete remission. To our surprise, CAR T cells were detected in CS1 CAR T-cell-treated mice. Although these persisting CAR T cells had low expression of exhaustion markers such as PD1 and Tim3, the levels were too low to prevent tumor relapse (data not shown). These data highlight the need for a strategy that can improve CAR T-cell function and expansion/persistence to achieve durable tumor remissions.
Lenalidomide has been shown to promote immunologic memory in the T-cell populations of patients with multiple myeloma by resulting in an excess of memory T cells and decrease of terminally differentiated T cells (38) . In agreement with others' observations (38) , our data showed that lenalidomide preferentially expanded CD8 þ CAR T cells, resulting in increased total cell expansion. The expanded CD8 þ CAR T cells exhibited less differentiated phenotypes but maintained minimal exhaustive features as reported (39) and terminal differentiation genes, suggesting that lenalidomide improves memory CAR T-cell maintenance.
Lenalidomide exerts a costimulatory effect on T-cell responses that includes increased production of IL2 and IFNg and inhibits production of anti-inflammatory cytokines (40, 41) . Consistently, in our studies, CAR T cells treated with lenalidomide exhibited a strong capacity to produce Th1 cytokines upon stimulation with different CS1 þ tumors such as U266B, MM.1S, and MM.1R; these cytokines are required for durable antitumor activity of T cells (42) . In contrast, Th2 cytokines that hamper the induction of effective T-cell responses (42, 43) were downregulated, demonstrating that lenalidomide can favorably moderate the immune milieu. Furthermore, lenalidomide-treated CAR T cells exhibited increased cytolysis of multiple myeloma cells. These effects may be attributed to the enhanced immune synapse formation between the lenalidomide-treated CAR T cells and tumors as is supported by gene signatures enriching for immune synapse formation and is in accordance with previous studies (44, 45) . In the murine model, we chose a relatively low dose of lenalidomide to allow assessment of potential synergistic effects when combined with CAR T-cell treatment. In spite of the suboptimal dose of lenalidomide in the NSG model as compared with the doses used by others (46, 47) , combination therapy completely eradicated tumor. Therefore, the combinatorial effects mainly reflect the impact of lenalidomide on CAR T cells. Patients treated with lenalidomide have shown faster CD8 þ T-cell reconstitution compared with CD4 þ cells (48) . Consistently, CD8 þ CAR T cells became dominant within the harvested human T cells from mice, which markedly differs from the CD4-dominant composition of input CAR T cells, further confirming our in vitro data showing CD8 þ CAR enrichment in the presence of lenalidomide. Pretreated CS1 CAR T cells exhibited similar antitumor activity to untreated CS1 CAR T cells in vivo, indicating the requirement of sustained lenalidomide to maintain the T-cell costimulatory pathway and obtain synergistic effects with CAR T cells.
We also noticed that recurrent tumors in mice that had received combination therapy had a different distribution pattern than tumors in mice treated with CS1 CAR T cells alone. Specifically, CS1 CAR T-cell-treated tumors were located mainly in the bone marrow; in contrast, mice with recurrent tumors from combination treatment had to be euthanized because of large extramedullary subcutaneous tumors where there were no CAR T cells detected (data not shown). Lenalidomide disrupts the microenvironmental interactions between multiple myeloma cells and bone marrow stromal cells (49) , resulting in inhibition of tumor growth. Our data suggest that lenalidomide may impair bone marrow microenvironmental support for multiple myeloma growth, directing the relapsed tumor to seed preferentially in extramedullary tissues. Evidently, CS1 CAR T cells did not penetrate into the metastasized extramedullary tumors and faced the same barriers presented by other types of solid tumors (50) .
In summary, this study provides novel mechanistic insights into CAR T-cell functional augmentation by lenalidomide in terms of in vivo antitumor activity and persistence. The synergistic effects could be the consequence of directly inhibiting tumorinitiating cells (SP) while enhancing the antitumor activity of CAR T cells. This study provides the basis for a planned clinical trial using the combination of lenalidomide with engineered T cells against CS1 in relapsed myeloma.
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